<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02279511</url>
  </required_header>
  <id_info>
    <org_study_id>ECA4A</org_study_id>
    <nct_id>NCT02279511</nct_id>
  </id_info>
  <brief_title>ATP in Alzheimer Disease</brief_title>
  <official_title>Evaluating the Effectiveness of the Use of Intravenous Infusions of Adenosine Triphosphate (ATP) in Patients With Moderate Alzheimer's Disease and Severe: Double-blind Dose Finding Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sara Varea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Clinic per a la Recerca Biomédica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To Check whether systemic treatment with ATP alters the profile of cerebral metabolism in
      patients with Alzheimer's disease using MRS techniques (Magnetic Resonance Spectroscopy) and
      adjust the infusion (minimum effective dose) that promotes this metabolic change.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of brain metabolic changes after ATP infusion by spectroscopy techniques (H + MRS)</measure>
    <time_frame>expected average of 7-25 hours post infusion</time_frame>
    <description>Spectroscopy will be taken one hour after the infusion (7h for patients allocated to 6h arm and 25h in 24h infusion arm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Cogstate results</measure>
    <time_frame>expected average of 7-25 hours post infusion</time_frame>
    <description>one hour after the infusion (7h for patients allocated to 6h arm and 25h in 24h infusion arm)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Cogstate results</measure>
    <time_frame>3 months compared to baseline.</time_frame>
    <description>The cogstate is a software used to evaluate cognitive impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in test Mini-Mental State Examination</measure>
    <time_frame>3 months compared to baseline.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in synaptic activity after treatment administration Neurological examination</measure>
    <time_frame>post treatment or 3 months post baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram results</measure>
    <time_frame>an expected average of 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>at 90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>24 hours infusion of ATP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6 hours infusion of ATP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>24 hours infusion of placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6 hours infusion of placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADENOSINE TRIPHOSPHATE</intervention_name>
    <description>Infusion of 2.5g of ATP in 500 mL of saline solution. (IV)</description>
    <arm_group_label>24 hours infusion of ATP</arm_group_label>
    <arm_group_label>6 hours infusion of ATP</arm_group_label>
    <other_name>ATP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>Infusion of 500 mL of saline solution. (IV)</description>
    <arm_group_label>24 hours infusion of placebo</arm_group_label>
    <arm_group_label>6 hours infusion of placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Men and women aged 55-85 years

          -  2. Diagnosis of possible or probable Alzheimer disease according to NIA-AA 2011
             criteria.

          -  3. Global Deterioration Scale Stadium 5-6 / 15-5 Mini-mental State examination

          -  4. The patient is living with a family as a primary caregiver or a caregiver trained
             to accompany adequate and all intervention and follow-up visits. Patient and caregiver
             knowledge of local languages sufficient.

          -  5. The patient and caregiver willing to participate in the study. There is a high
             probability that patient and caregiver to complete the study.

          -  6. The patient has no sensory deficits preventing evaluation.

          -  7. The patient receives a stable Alzheimer Disease conventional medication. No change
             in treatment at least 90 days prior to selection.

          -  8. The patient receives a conventional stable medication for possible comorbidities.
             No change in treatment at least 90 days prior to selection.

          -  9. The subject or his legal representative give prior informed consent that includes
             genetic studies of Apolipoprotein E and rs11870474.

        Exclusion Criteria:

          -  1. Concomitant severe neurological disease Alzheimer Disease.

          -  2. Presence or history of psychiatric disorders with an emphasis on positive
             behavioral disorders associated with Alzheimer Disease (aggressiveness, agitation,
             delusions, hallucinations, anxiety).

          -  3. Current Severe systemic disease that may prevent completion of the study.

          -  4. History STROKE.

          -  5. History of convulsions and use of anticonvulsants.

          -  6. History of myocardial infarction, angina pectoris, cardiac arrhythmias and other
             serious cardiovascular disorders such as congestive heart failure, and valvular
             aneurysms.

          -  7. Background Diabetes mellitus and / or pictures of hypoglycemia.

          -  8. Uncontrolled hypertension (systolic&gt; 160 mmHg and / or Diastolic&gt; 95 mmHg).

          -  9. Systemic hypotension (SBP &lt;86 mmHg) or bradycardia (&lt;50 beats per minute)

          -  10. Bronchial Asthma History or lung diseases that cause bronchospasm or
             bronchoconstriction

          -  11. Kidney failure (patients with medical restrictions or income parenteral intake of
             fluids).

          -  12. Liver failure.

          -  13. Respiratory failure (need supplemental oxygen supply)

          -  14. Blood donation in the last 90 days or anemia (Hb &lt;10g/dL)

          -  15. Use connection (&lt;30 days prior to screening) of antidepressants, sedatives and
             hypnotics.

          -  16. Using Alzheimer Disease experimental drugs in the last 60 days prior to screening.

          -  17. Women who are pregnant or fertile

          -  18. Inadequate venous access to prevent parenteral administration of infusions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mercè Boada Rovira, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació ACE. Barcelona Alzheimer Treatment and Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundació ACE</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sanitas CIMA</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2014</study_first_submitted>
  <study_first_submitted_qc>October 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2014</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinic per a la Recerca Biomédica</investigator_affiliation>
    <investigator_full_name>Sara Varea</investigator_full_name>
    <investigator_title>Clinical Trial Manager</investigator_title>
  </responsible_party>
  <keyword>Alzheimer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

